Drug Formulary Committee
Consent Agenda Policy

Consent agenda items will be presented to the Drug Formulary Committee (DFC) in a single motion for a yes or no vote after allowing any DFC voting member the opportunity to request that one or more specific items be moved to the full agenda for discussion and a separate vote. The DFC chair may determine where on the agenda those items removed from the consent agenda will be discussed.

Meeting items may be proposed as consent agenda items if any of the following applies:

- For Uniform Preferred Drug List revisions:
    - A revision will result in expanded access to a drug by moving it from a non-preferred status to a preferred status or an unlisted status to a preferred status.
    - A revision is moving the brand and generic formulations of a drug to the preferred status to the non-preferred status and vice versa so long as one formulation remains preferred (i.e. generic substitution or brand preferred over the generic).
    - A revision would add a new generic drug or biosimilar to the PDL, with the same status as the current brand or innovator drug on the PDL.
    - A revision is to correct clerical errors or to remove obsolete or discontinued drugs.

- For Prior Authorization Criteria Sheet revisions:
    - A revision will result in expanded access to a drug. Examples may include changes like expanding the approval criteria to include a new FDA-approved indication or removing the prior authorization criteria on a drug.
    - A revision to the PA criteria sheet to correct clerical errors or provide clarification.

- For new Prior Authorization Criteria Sheets:
    - A new Prior Authorization Criteria sheet that is drafted in accordance with FDA-approved label

DFC Review: 12/7/2023